

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Akesobio

Akeso, Inc.

康方生物科技(開曼)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF DR. MICHAEL (CHEN) CHEN AS BUSINESS DEVELOPMENT VICE PRESIDENT

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce the appointment of Dr. Michael (Chen) Chen (“**Dr. Chen**”) as business development vice president of the Company. Dr. Chen has extensive experience in global business development. He will be responsible for overseeing the global business development of the Company. The joining of Dr. Chen means the Company will further strengthen pipeline cooperation and business development and will speed up the process of commercialization, which will enhance the core competitiveness and global business layout of the Group.

Dr. Chen has dedicated himself to biopharmaceutical industry and global business development for years and has extensive experience and practical achievements in external innovation, pipeline cooperation and business development. Before joining the Company, Dr. Chen worked as Head of External Innovation APAC for Merck KGaA. (“**Merck**”), where he promoted the cooperation opportunities for pipeline research and development of Merck through liaison with pharmaceutical companies, biotechnology companies, professional investors and outstanding academic research centers in China and APAC areas. Meanwhile, Dr. Chen was also responsible for the international business development department of Merck in China and APAC areas, carrying out a variety of internal and external business cooperation. Dr. Chen drives commercial cooperation for different types

of projects through open innovation, licensing, co-development, investment, and other collaboration models. Dr. Chen was also one of the leading members of Merck Asia and China research and development center, from which he worked along with R&D team for Merck's own pipeline in regional development, and alliance management of external collaborations. Dr. Chen was also one of the core members for expanding Merck's oncology business and innovation collaboration in China.

Dr. Chen received his bachelor's degree in cell and molecular biology from the University of Essex in the United Kingdom, a master's degree in cancer immunotherapy from the University of Nottingham in the United Kingdom and a PhD in Biochemistry from Imperial College London in the United Kingdom. Before joining Merck, Dr. Chen led research projects at Spirogen Ltd. (a biotechnology company in the United Kingdom which was subsequently acquired by MedImmune LLC, a subsidiary of AstraZeneca engaging in global biopharmaceutical business). After returning to China, he joined Wuxi Biologics and ChemPartner and was responsible for business development and investment.

The Board wishes to take this opportunity to warmly welcome Dr. Chen to the Group.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, July 30, 2020

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Mr. LIN Lijun and Dr. ZHOU Yi as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.